Table 3.

Multivariate Cox regression models for early death, achievement of CR, and RFS/OS among all patients with “AML, NOS” regardless of NPM1 and CEBPA status

Parameter	Early death*,†	CR*	RFS*	OS*
M1	1.06 (0.68-1.65), P = .79	1.47 (1.13-1.93), P = .0047	0.85 (0.71-1.00), P = .057	0.82 (0.72-0.94), P = .0033
M2	0.83 (0.52-1.31), P = .42	1.73 (1.32-2.26), P < .001	0.83 (0.70-0.98), P = .029	0.78 (0.68-0.89), P < .001
M4	1.05 (0.66-1.66), P = .84	1.64 (1.24-2.17), P < .001	0.91 (0.76-1.08), P = .28	0.86 (0.75-0.98), P = .027
M5	1.28 (0.80-2.05), P = .30	2.02 (1.50-2.73), P < .001	0.88 (0.73-1.05), P = .16	0.83 (0.72-0.96), P = .011
M6	0.50 (0.19-1.27), P = .14	1.70 (1.10-2.63), P = .017	1.00 (0.78-1.28), P = .99	0.89 (0.73-1.10), P = .28
M7	0.41 (0.05-3.18), P = .39	0.71 (0.34-1.47), P = .35	1.22 (0.76-1.97), P = .42	1.34 (0.94-1.92), P = .11
Age	1.06 (1.05-1.07), P < .001	0.95 (0.95-0.96), P < .001	1.02 (1.02-1.02), P < .001	1.03 (1.03-1.03), P < .001
WBC	1.00 (1.00-1.01), P < .001	1.00 (1.00-1.00), P < .001	1.00 (1.00-1.00), P < .001	1.00 (1.00-1.00), P < .001
Platelets	1.00 (1.00-1.00), P = .64	1.00 (1.00-1.00), P = .28	1.00 (1.00-1.00), P = .012	1.00 (1.00-1.00), P = .077
Bone marrow blasts	1.00 (1.00-1.01), P = .13	1.00 (1.00-1.00), P = .50	1.00 (1.00-1.00), P = .0074	1.00 (1.00-1.00), P < .001
Male gender	1.09 (0.88-1.34), P = .44	0.91 (0.80-1.04), P = .18	1.09 (1.02-1.18), P = .018	1.05 (0.98-1.11), P = .16
PS = 1	1.14 (0.88-1.48), P = .32	0.75 (0.65-0.88), P < .001	0.98 (0.90-1.07), P = .62	1.05 (0.97-1.13), P = .22
PS ≥ 2	2.95 (2.25-3.87), P < .001	0.49 (0.41-0.60), P < .001	1.15 (1.03-1.28), P = .013	1.44 (1.32-1.57), P < .001
Abnormal karyotype	1.13 (0.89-1.43), P = .32	0.67 (0.58-0.78), P < .001	1.15 (1.06-1.25), P = .0013	1.25 (1.16-1.34), P < .001

^*Data are presented as OR or HR (95% CI), as appropriate.

^†Death within 28 d after initiation of therapy or study registration (if exact date of initiation of therapy was unknown).